240 related articles for article (PubMed ID: 20200556)
1. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation.
Singh RR; Kim JE; Davuluri Y; Drakos E; Cho-Vega JH; Amin HM; Vega F
Leukemia; 2010 May; 24(5):1025-36. PubMed ID: 20200556
[TBL] [Abstract][Full Text] [Related]
2. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma.
Qu C; Liu Y; Kunkalla K; Singh RR; Blonska M; Lin X; Agarwal NK; Vega F
Blood; 2013 Jun; 121(23):4718-28. PubMed ID: 23632891
[TBL] [Abstract][Full Text] [Related]
3. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
[TBL] [Abstract][Full Text] [Related]
4. Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma.
Ramirez E; Singh RR; Kunkalla K; Liu Y; Qu C; Cain C; Multani AS; Lennon PA; Jackacky J; Ho M; Dawud S; Gu J; Yang S; Hu PC; Vega F
Leuk Res; 2012 Oct; 36(10):1267-73. PubMed ID: 22809693
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells.
Kobune M; Takimoto R; Murase K; Iyama S; Sato T; Kikuchi S; Kawano Y; Miyanishi K; Sato Y; Niitsu Y; Kato J
Cancer Sci; 2009 May; 100(5):948-55. PubMed ID: 19245435
[TBL] [Abstract][Full Text] [Related]
6. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis.
Chen X; Horiuchi A; Kikuchi N; Osada R; Yoshida J; Shiozawa T; Konishi I
Cancer Sci; 2007 Jan; 98(1):68-76. PubMed ID: 17083567
[TBL] [Abstract][Full Text] [Related]
8. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes.
Bai M; Skyrlas A; Agnantis NJ; Kamina S; Kitsoulis P; Kanavaros P
Anticancer Res; 2004; 24(5A):3081-8. PubMed ID: 15517919
[TBL] [Abstract][Full Text] [Related]
9. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway.
Ray DM; Morse KM; Hilchey SP; Garcia TM; Felgar RE; Maggirwar SB; Phipps RP; Bernstein SH
Exp Hematol; 2006 Sep; 34(9):1202-11. PubMed ID: 16939813
[TBL] [Abstract][Full Text] [Related]
10. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
11. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.
Ruminy P; Etancelin P; Couronné L; Parmentier F; Rainville V; Mareschal S; Bohers E; Burgot C; Cornic M; Bertrand P; Lenormand B; Picquenot JM; Jardin F; Tilly H; Bastard C
Leukemia; 2011 Apr; 25(4):681-8. PubMed ID: 21233831
[TBL] [Abstract][Full Text] [Related]
12. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
Singh RR; Kunkalla K; Qu C; Schlette E; Neelapu SS; Samaniego F; Vega F
Oncogene; 2011 Dec; 30(49):4874-86. PubMed ID: 21625222
[TBL] [Abstract][Full Text] [Related]
13. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
14. B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas.
Bai M; Skyrlas A; Agnantis NJ; Kamina S; Papoudou-Bai A; Kitsoulis P; Kanavaros P
Anticancer Res; 2005; 25(1A):347-62. PubMed ID: 15816558
[TBL] [Abstract][Full Text] [Related]
15. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link.
Kuttler F; Valnet-Rabier MB; Angonin R; Ferrand C; Deconinck E; Mougin C; Cahn JY; Fest T
Leukemia; 2002 Apr; 16(4):726-35. PubMed ID: 11960356
[TBL] [Abstract][Full Text] [Related]
16. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
17. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of miR-21 induces biological and behavioral alterations in diffuse large B-cell lymphoma.
Gu L; Song G; Chen L; Nie Z; He B; Pan Y; Xu Y; Li R; Gao T; Cho WC; Wang S
Acta Haematol; 2013; 130(2):87-94. PubMed ID: 23548551
[TBL] [Abstract][Full Text] [Related]
19. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
20. BCL2 mutations in diffuse large B-cell lymphoma.
Schuetz JM; Johnson NA; Morin RD; Scott DW; Tan K; Ben-Nierah S; Boyle M; Slack GW; Marra MA; Connors JM; Brooks-Wilson AR; Gascoyne RD
Leukemia; 2012 Jun; 26(6):1383-90. PubMed ID: 22189900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]